Loading market dashboard
Emera Incorporated
EMAUtilitiesNYSECA
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility PR Newswire SINGAPORE,
Johnson and Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2
Johnson and Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (MonjuviÂ/Min
[url="]BeOne Medicines Ltd.[/url] (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocyti
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (TSX/NYSE: EMA) announced that at its Annual Meeting of Shareholders held on May 21, 2026, on a vote by ballot, each of the 11 nominees proposed as Directors and listed in its Management Information Circular dated as of March 19, 2026 were elected as Directors. The detailed results of the vote for the election of Directors are set out below. Nominee Votes For Votes Withheld Number Percent Number Percent Scott C. Balfour 158,298,930 99.75% 390,.
Emera Incorporated (EMA:CA) Shareholder/Analyst Call Transcript
Hansa Biopharma enters into â¬115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA PR New
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today, May 8, 2026, Emera Inc. (“Emera”) (TSX/NYSE: EMA) reported 2026 first quarter financial results1. Highlights Delivered a 7% increase in adjusted earnings per share2 (“EPS”), with $1.37 in Q1 2026, compared to $1.28 in Q1 2025, and reported EPS of $1.85 compared to $1.96 in Q1 2025. On track to deliver 2026 adjusted EPS2 growth above our earnings guidance range of 5-7%3 annualized. Capital plan on track: Deployed more than $870 million of our $4.0 bi.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Incorporated (“Emera” or the “Company”) (TSX/NYSE: EMA) announced today that after having taken into account all conversion notices received from holders of its outstanding Cumulative Minimum Rate Reset First Preferred Shares, Series J (the “Series J Shares”) by the April 30, 2026 deadline for conversion notices, less than the 1,000,000 Series J Shares required to give effect to conversions into Cumulative Floating Rate First Preferred Shares, Series.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today, Emera Inc. (TSX/NYSE:EMA) announced that Judy Steele, President and Chief Operating Officer of Emera Energy, will retire effective June 30, after 26 years with Emera. Over her career with Emera, Judy held several senior leadership roles, including Chief Financial Officer of Emera Inc., and spent the past 14 years leading Emera Energy. During her tenure, Emera Energy expanded its footprint across North America, increased its contribution to Emera's o.
Novartis secures CHMP backing for Itvisma in SMA and wins WHO nod for Coartem Baby, targeting critical gaps in rare disease and infant malaria care.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Incorporated (“Emera” or the “Company”) (TSX/NYSE: EMA) announced today the applicable dividend rates for its Cumulative Minimum Rate Reset First Preferred Shares, Series J (the “Series J Shares”) and Cumulative Floating Rate First Preferred Shares, Series K (the “Series K Shares”), in each case, payable if, as and when declared by the Board of Directors of the Company: 6.345% per annum on the Series J Shares ($0.3966 per Series J Share per quarter),.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--On April 13, 2026, the Board of Directors of Emera Inc. (TSX/NYSE: EMA) declared quarterly dividends on its common shares and First Preferred Shares, each of which is payable on and after May 15, 2026 to the applicable shareholders of record at the close of business on May 1, 2026, as follows: $0.7325 per common share; $0.3094 per Series A First Preferred Share; $0.40213 per Series C First Preferred Share; $0.28125 per Series E First Preferred Share; $0.35.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Incorporated (“Emera” or the “Company”) (TSX/NYSE: EMA) announced today that it does not intend to exercise its right to redeem all or any part of the currently outstanding Cumulative Minimum Rate Reset First Preferred Shares, Series J of the Company (the “Series J Shares”) on May 15, 2026. There are currently 8,000,000 Series J Shares outstanding. Subject to certain conditions set out in the prospectus supplement of the Company dated March 26, 2021,.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today Emera (TSX/NYSE: EMA) announced that it will release its Q1 2026 results on Friday, May 8, 2026, before markets open. The Company will host a teleconference and webcast the same day at 9:30 a.m. Atlantic (8:30 a.m. Eastern) to discuss the results. Analysts and other interested parties in North America are invited to participate by dialing 1-800-717-1738. International parties are invited to participate by dialing 1-289-514-5100. Participants should d.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Incorporated (“Emera” or the “Company”) (TSX/NYSE: EMA) announced today that Emera US Finance, LLC (the “Issuer”) has completed the sale of US$750 million aggregate principal amount of United States dollar denominated senior notes, consisting of US$450 million aggregate principal amount of 4.500% senior notes due 2029 (the “2029 Notes”) and US$300 million aggregate principal amount of 5.200% senior notes due 2033 (the “2033 Notes” and, together with.
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Incorporated (“Emera” or the “Company”) (TSX/NYSE: EMA) announced today that Emera US Finance, LLC (the “Issuer”) has completed the sale of US$750 million aggregate principal amount of United States dollar denominated junior subordinated notes, consisting of US$375 million aggregate principal amount of 6.650% Series A fixed-to-fixed reset rate junior subordinated notes due 2056 (the “Series A Notes”) and US$375 million aggregate principal amount of 6.
